Curated News
By: NewsRamp Editorial Staff
January 16, 2026
Diagnos Partners with Investor Brand Network to Boost AI Healthcare Profile
TLDR
- Diagnos Inc. gains a strategic edge by engaging IBN to enhance market awareness and maximize shareholder value through targeted corporate communications.
- Diagnos Inc. has contracted IBN for a one-year corporate communication service starting January 10, 2026, with monthly payments of US$6,400, pending TSX Venture Exchange approval.
- Diagnos Inc.'s AI technology improves global healthcare by enabling earlier detection of eye diseases, leading to better patient outcomes and more efficient clinical workflows.
- Diagnos Inc. uses artificial intelligence to detect critical eye health issues early, partnering with IBN to amplify its innovative approach to preventive healthcare.
Impact - Why it Matters
This news matters because it represents a strategic move by a healthcare technology company to increase visibility and investor engagement, which can accelerate the adoption of AI-driven diagnostic tools. For patients and healthcare providers, enhanced market awareness could lead to broader implementation of Diagnos's technology, potentially improving early detection of critical eye conditions like diabetic retinopathy or glaucoma on a global scale. For investors, the partnership signals proactive management and growth potential, while for the medical community, it highlights the ongoing integration of AI in improving diagnostic accuracy and patient outcomes. In an era where healthcare innovation relies on both technological advancement and effective communication, such collaborations can bridge the gap between cutting-edge solutions and real-world impact.
Summary
Diagnos Inc., a Canadian publicly traded corporation listed on the TSX Venture Exchange (ADK), OTCQB (DGNOF), and FWB (4D4A), has announced a strategic partnership with Investor Brand Network (IBN) to enhance its corporate communications and market awareness. As a pioneer in early detection of critical eye-related health issues using Artificial Intelligence-based technology, Diagnos aims to leverage IBN's specialized services to refine its market profile and maximize shareholder value. The one-year agreement, effective January 10, 2026, involves monthly compensation of US$6,400 payable in advance from the Corporation's funds, and remains subject to acceptance by the TSX Venture Exchange. IBN, which operates at arm's length and holds no direct or indirect interest in Diagnos's securities, will provide comprehensive solutions including wire-grade press release syndication, article and editorial syndication to over 5,000 outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and tailored corporate communications solutions.
This engagement highlights Diagnos's commitment to advancing its mission of improving global healthcare through AI-driven diagnostic tools that enhance accuracy, streamline workflows, and improve patient outcomes. The company's focus on early detection of eye-related health problems positions it at the forefront of medical technology innovation. Additional information about Diagnos is available through its corporate website and regulatory filings, while updates relating to DGNOF can be found in the company's newsroom. The partnership with IBN, part of the Dynamic Brand Portfolio, underscores the importance of effective communication in the competitive healthcare and investment landscapes, aiming to cut through information overload and bring unparalleled recognition to Diagnos's groundbreaking work.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Diagnos Partners with Investor Brand Network to Boost AI Healthcare Profile
